市场调查报告书
商品编码
1371987
2030 年脑监测市场预测:按设备、配件、可用性、医疗状况、最终用户和地区进行的全球分析Brain Monitoring Market Forecasts to 2030 - Global Analysis By Device (Type, Procedure and Other Devices), Accessories, Usability, Medical Condition, End User and By Geography |
根据 Stratistics MRC 的数据,2023 年全球脑监测市场规模将达到 68 亿美元,预计到 2030 年将达到 120 亿美元,预测期内年复合成长率为 8.5%。
大脑监测方法旨在获取有关大脑的电、动态、代谢和解剖学特征的资料,以帮助诊断、治疗、研究和理解许多神经系统疾病和失调。脑电图(EEG)、脑磁图(MEG)、功能性磁振造影(fMRI)、近红外线光光谱(NIRS)、正子断层扫描(PET)和其他非侵入性或微创技术只是其中的一个例子。许多非侵入性或微创技术用于大脑监测技术。
根据世界卫生组织资料,截至2019年9月,全球约有5,000万人罹患失智症,每年新增近1,000万例失智症病例。它是世界各地老年人残疾和依赖的主要原因之一。
随着脑部监测技术的快速发展,小工具的准确性、清晰度和效用都提高了。 EEG、MEG、fMRI、NIRS 和其他技术的改进正在开发更复杂、更可靠的监测系统。此外,颅内压升高是未来脑损伤的关键要素,使得 ICP检测成为脑外伤后头部影像的重要组成部分。这些发展吸引了学者和医疗保健专业人士,并推动了业务成长。
阻碍全球大脑监测市场成长的另一个挑战是缺乏具有操作大脑监测设备所需专业知识的人力资源。全球脑监测市场面临的主要挑战之一是缺乏高技能和受过教育的工人,限制了该行业在新兴市场和发展中国家的成长。因此,全球范围内对高技能和训练有素的工人的需求不断增加。
非洲大陆巨大的人口老化导致了与老龄化相关的神经系统疾病的流行。脑监测技术可以协助早期发现和监测认知能力下降,支持医疗专业人员制定个人化治疗计画并提示治疗。随着年龄的进行性,进行性神经系统疾病变得更加常见。此外,镰状细胞性贫血和心臟异常等新疾病的发生频率正在增加,推动了市场的扩张。
缺乏必要的医疗基础设施、高昂的医疗成本以及植入应用的安全问题都可能成为大脑监测设备市场扩张的要素。这些设备可能很难使用,使用这些设备的价格可能很高。产品的采用可能会因报销程序不足或严格的政府法规而受到阻碍。
COVID-19大流行不仅对医疗保健系统产生了重大影响,也对大脑监测设备市场产生了重大影响。由于全球封锁,神经系统检查被推迟或取消,这对帕金森氏症和癫痫患者及其获得治疗的机会产生了负面影响。然而,随着大脑监测服务的恢復和病例的减少,市场预计将从大流行中復苏。
创伤性脑损伤(TBI)预计将成为预测期内最大的领域。 TBI 在全球范围内的日益患病,导致对这些病例的护理需求很高,并需要广泛使用大脑监测设备,这正在推动这一领域市场的重要份额。Masu。此外,已开发国家增加执行新程序的临床研究和尖端设备的核准预计将刺激该领域的扩张。
预计医院领域在预测期内复合年复合成长率最高。大脑监测的复杂过程需要使用医院常见的高科技和昂贵的设备。儘管医院比其他最终用户更有能力承受这些费用,但大脑监测技术仍然给医疗机构带来了巨大的财务负担。因此,医院在该市场类别中占据最大比例,是脑监测设备的主要用户。
预计北美在预测期内将占据最大的市场占有率。这是由于神经系统疾病的增加、脑监测设备临床试验的扩大以及美国医疗保险的便利性。强大的医疗基础设施、不断上升的医疗成本和高龄化都是该地区的优势,也是市场开拓的关键促进因素。该地区脑部疾病发生率较高,主要企业不断推出产品预计将对市场成长产生正面影响。
预计亚太地区在预测期内将维持最高的年复合成长率。由于有利的报销政策的存在,预计市场将在预测期内大幅扩张,特别是在其他某些地区。该地区拥有强大的医疗基础设施,并且可能会看到技术进步。随着监控设备领域的深入研究,市场很快就能购买到具有尖端功能的小工具。
According to Stratistics MRC, the Global Brain Monitoring Market is accounted for $6.8 billion in 2023 and is expected to reach $12.0 billion by 2030 growing at a CAGR of 8.5% during the forecast period. Brain monitoring methods attempt to obtain data on the electrical, hemodynamic, metabolic, or anatomical features of the brain to help with the diagnosis, treatment, study, and comprehension of many neurological illnesses and disorders. Electroencephalography (EEG), magnetoencephalography (MEG), functional magnetic resonance imaging (fMRI), near-infrared spectroscopy (NIRS), positron emission tomography (PET), and other non-invasive or minimally invasive techniques are only a few examples of the numerous non-invasive or minimally invasive techniques used in brain monitoring technology.
According to WHO data, as of September 2019, around 50 million people are affected by dementia globally, with nearly 10 million new cases registered each year. It is one of the major causes of disability and dependency among older people worldwide.
The fast developments in brain monitoring technology have all enhanced the gadgets' accuracy, clarity, and usefulness. Improvements in EEG, MEG, fMRI, NIRS, and other techniques have led to the development of more sophisticated and reliable monitoring systems. Additionally, since increased intracranial pressure is a significant contributor to future brain damage, ICP measurement has become a crucial component of head imaging in the aftermath of brain trauma. These developments attract academics and healthcare specialists, promoting business growth.
Another challenge impeding the growth of the global market for brain monitoring is a paucity of personnel with the requisite expertise to operate brain monitoring equipment. One of the main problems the global brain monitoring market has is a dearth of highly skilled or educated workers, which limits the industry's growth in developing and growing nations. As a result, there is an increase in demand for highly skilled or trained workers on a worldwide level.
Due to the continent's huge geriatric population, age-related neurological illnesses are more prevalent. Brain monitoring technology can support medical professionals in creating individualized treatment plans and speedy therapies by helping in the early detection and monitoring of cognitive loss. Progressive neurological diseases and illnesses are more common as people age. Additionally, the frequency of additional ailments is rising, such as sickle-cell anemia and heart abnormalities, which fuels market expansion.
The lack of essential healthcare infrastructure, high medical costs, and safety concerns with implant applications might all act as inhibitors to the expansion of the market for brain monitoring devices. The equipment is fairly challenging to use, and these devices may be pricey to utilize. Adoption of a product might be hampered by poor reimbursement procedures and onerous governmental rules.
The COVID-19 pandemic had a large effect on the healthcare system, as well as the market for brain monitoring equipment. Due to the worldwide lockdown, neurological examinations were postponed or cancelled, which had an adverse effect on Parkinson's patients as well as those with epilepsy and their access to care. The market is anticipated to rebound from the pandemic's fall, though, when brain monitoring services restarted and cases declined.
The traumatic brain injury (TBI) segment is expected to be the largest during the forecast period. The increasing prevalence of TBIs worldwide, which has resulted in a high demand for the care of these cases and necessitated the extensive use of brain monitoring equipment, is a significant cause behind the substantial share of this market sector. Additionally, it is anticipated that a combination of rising clinical studies for implementing new procedures and rising approvals of the newest gadgets in developed nations would fuel the segment's expansion.
The hospitals segment is expected to have the highest CAGR during the forecast period. The intricate process of brain monitoring necessitates the use of high-tech, pricey equipment that is often found in hospitals. Hospitals are more equipped to tolerate these expenditures than other end-users, but brain monitoring technologies still place a significant financial strain on healthcare institutions. Therefore, hospitals account for the greatest proportion of this market category and are the primary users of brain monitoring equipment.
North America is projected to hold the largest market share during the forecast period. This is explained by the rise in neurological disorders, the expansion of brain monitoring device clinical trials, and the accessibility of medical insurance in the US. A strong healthcare infrastructure, increased healthcare spending, and an aging population are all advantages for the area and major market development drivers. A high frequency of brain diseases in the area and ongoing product releases by key companies are also anticipated to positively affect market growth.
Asia Pacific is projected to hold the highest CAGR over the forecast period. Especially in certain other locations, the availability of advantageous reimbursement policies would cause the market to see considerable expansion throughout the projection period. Because of this area's strong healthcare infrastructure, technological advancements are conceivable. The market will soon be able to purchase gadgets with cutting-edge features thanks to significant research in the field of monitoring devices.
Some of the key players in Brain Monitoring Market include: Masimo Corporation, Natus Medical Incorporated, Advanced Brain Monitoring Inc., Nihon Kohden Corporation, Compumedics, Integra Lifesciences Corporation, Medtronic PLC, Koninklijke Philips NV, Nonin Medical Inc., Cadwell Industries Inc., Cerenion Oy, General Electric Company, Siemens Healthcare Private Limited, Yokogawa Electric Corporation, Electrical Geodesics, Koninklijke Philips N. And Advanced Brain Monitoring Inc.
In November 2022, Neurosteer Inc. received FDA clearance for its Neurosteer single-channel EEG brain monitoring platform. This clearance enables the use of Neurosteer's unobtrusive multi-purpose system in a broad range of clinical settings.
In February 2022, Masimo received FDA clearance for its SedLine brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG Sensor. This clearance expands the potential benefits of SedLine to all patients, one-year-old and above, in the United States.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.